<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592016</url>
  </required_header>
  <id_info>
    <org_study_id>FDA02_Aim3</org_study_id>
    <secondary_id>2020-002101-25</secondary_id>
    <nct_id>NCT04592016</nct_id>
  </id_info>
  <brief_title>Evaluate the Ability of dOFM for BE Testing of Topically Applied Diclofenac Sodium Products in Healthy Subjects</brief_title>
  <official_title>A Single Center, Open-label, Clinical Study to Evaluate the Ability of Dermal Open Flow Microperfusion (dOFM) for Bioequivalence Testing of Topically Applied Diclofenac Sodium Products in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joanneum Research Forschungsgesellschaft mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Joanneum Research Forschungsgesellschaft mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single center, open label, exploratory research study to assess the dermal&#xD;
      pharmacokinetic (PK) profile of three marketed diclofenac products in 26 healthy volunteers&#xD;
      using dermal open flow microperfusion (dOFM).&#xD;
&#xD;
      This clinical study aims to assess bioequivalence (BE) of three different diclofenac&#xD;
      products.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study is divided into a pilot and a pivotal study. The pilot study will involve&#xD;
      6 healthy adult volunteers. The pilot study aims to develop the optimal study design for the&#xD;
      pivotal study by defining the dose of the reference product (diclofenac sodium gel 1%) and by&#xD;
      evaluating the absence of significant systemic cross-talk (systemic redistribution) and&#xD;
      lateral diffusion (cross-talk between adjacent treatment sites), which could increase&#xD;
      background drug levels in the dermis that might confound the discrimination of dermal PK&#xD;
      profiles between different products. Additionally, the suitability of a non-equivalent test&#xD;
      product to serve as negative control for BE relative to the reference product will be&#xD;
      evaluated.&#xD;
&#xD;
      The pivotal study will involve 20 healthy adult volunteers. In each volunteer the dermal PK&#xD;
      profile of three different diclofenac products will be assessed in 6 topical treatment sites&#xD;
      using dermal open flow microperfusion (dOFM), where the diclofenac penetration will be&#xD;
      measured from baseline to 12 h post-dose. BE of the reference product against a generic test&#xD;
      product (positive control) and against a non-equivalent test product (negative control) will&#xD;
      be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the dermal concentration versus time curve for diclofenac (pilot study: 6 participants, pivotal study: 20 participants)</measure>
    <time_frame>25 hours (pilot study), 13 hours (pivotal study)</time_frame>
    <description>Dermal concentrations (ng/mL) of diclofenac will be measured to calculate the area under the dermal concentration versus time curve AUC (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal dermal concentration of diclofenac (pilot study: 6 participants, pivotal study: 20 participants)</measure>
    <time_frame>25 hours (pilot study), 13 hours (pivotal study)</time_frame>
    <description>Dermal concentrations (ng/mL) of diclofenac will be measured to calculate the maximal dermal concentration (ng/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood diclofenac concentrations versus time curve (pilot study: 6 participants, pivotal study: 20 participants)</measure>
    <time_frame>25 hours (pilot study), 13 hours (pivotal study)</time_frame>
    <description>Diclofenac concentrations (ng/mL) in the blood will be measured to obtain the concentration-time curves in the blood.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pilot Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 6 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pivotal Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 20 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voltaren - Diclofenac sodium gel 1% (GSK, USA)</intervention_name>
    <description>Topical application in dermal-sampling visit</description>
    <arm_group_label>Pilot Study</arm_group_label>
    <arm_group_label>Pivotal Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)</intervention_name>
    <description>Topical application in dermal-sampling visit</description>
    <arm_group_label>Pilot Study</arm_group_label>
    <arm_group_label>Pivotal Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac sodium gel 1% (Perrigo, USA)</intervention_name>
    <description>Topical application in dermal-sampling visit</description>
    <arm_group_label>Pivotal Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermal open flow microperfusion - Pilot</intervention_name>
    <description>Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.</description>
    <arm_group_label>Pilot Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermal open flow microperfusion - Pivotal</intervention_name>
    <description>Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.</description>
    <arm_group_label>Pivotal Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling - Pilot</intervention_name>
    <description>1 sample is taken pre-dose and 24 samples are taken post-dose.</description>
    <arm_group_label>Pilot Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling - Pivotal</intervention_name>
    <description>1 sample is taken pre-dose and 12 samples are taken post-dose.</description>
    <arm_group_label>Pivotal Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, adult volunteers of age 18 to 65 years (both inclusive).&#xD;
&#xD;
          2. Males or non-pregnant, non-breast feeding females using adequate contraceptive methods&#xD;
             or abstinence.&#xD;
&#xD;
          3. Able to read, understand and sign the written informed consent form.&#xD;
&#xD;
          4. Willing to follow the protocol requirements and comply with protocol restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Social habits&#xD;
&#xD;
               1. Smoker who is not willing to refrain from smoking during the in-house visit.&#xD;
&#xD;
               2. History of drug and/or alcohol abuse within one year of start of study as judged&#xD;
                  by the investigator.&#xD;
&#xD;
          2. Medications: Use of any medications other than hormonal contraceptive, hormone&#xD;
             replacement therapy or routine vitamins within the 7 days or 5 half-life periods&#xD;
             whichever is longer prior to the initial dose of study medication.&#xD;
&#xD;
          3. Diseases: Presence of any clinically relevant acute or chronic disease, which in the&#xD;
             investigator´s opinion might jeopardise subject's safety, evaluation of results or&#xD;
             compliance with the protocol.&#xD;
&#xD;
          4. Any reason, which in the opinion of the investigator, would prevent the subject from&#xD;
             safely participating in the study.&#xD;
&#xD;
          5. Any abnormalities found during physical examination or vital signs, unless deemed not&#xD;
             clinically significant by the investigator.&#xD;
&#xD;
          6. Clinically significant abnormal laboratory evaluation results, as deemed by the&#xD;
             investigator.&#xD;
&#xD;
          7. Clinically significant abnormal 12-lead ECG at screening, as deemed by the&#xD;
             investigator.&#xD;
&#xD;
          8. Positive results to the test for hepatitis B antigen or hepatitis C antibodies.&#xD;
&#xD;
          9. Positive HIV test.&#xD;
&#xD;
         10. Positive alcohol breath test.&#xD;
&#xD;
         11. Blood donation within 30 days or significant loss of blood or plasma (more than 550&#xD;
             ml) within 90 days prior to screening.&#xD;
&#xD;
         12. Subjects who have received an investigational drug within 30 days prior to the initial&#xD;
             dose of study medication.&#xD;
&#xD;
         13. Known hypersensitivity to diclofenac or any components of the drugs.&#xD;
&#xD;
         14. Tattoos or broken and/or damaged skin and/or scarring at the application areas.&#xD;
&#xD;
         15. Active skin diseases like psoriasis or atopic dermatitis, as judged by the&#xD;
             investigator.&#xD;
&#xD;
         16. Subjects prone to keloid or hypertrophic scar formation or any known wound healing&#xD;
             disorder.&#xD;
&#xD;
         17. Recent and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of&#xD;
             fainting, palpitations, etc.), as judged by the investigator.&#xD;
&#xD;
         18. Not willing to avoid excessive sun exposure, steam baths, sauna, swimming and other&#xD;
             strenuous activities for 14 days after Visit 2 to ensure good tissue regeneration.&#xD;
&#xD;
         19. Not willing to refrain from shaving the planned treatment sites or using skin care&#xD;
             products on the planned treatment sites for at least 5 days prior to start of Visit 2.&#xD;
&#xD;
         20. Pronounced hairiness on the planned treatment sites that may negatively affect BE&#xD;
             testing.&#xD;
&#xD;
         21. Known allergy/hypersensitivity to any of the materials/supplies used during the study.&#xD;
&#xD;
         22. Presence of needle phobia.&#xD;
&#xD;
         23. Increased risk of thrombosis, e.g. personal or first degree relative(s) history of&#xD;
             deep vein thrombosis.&#xD;
&#xD;
         24. Not enough space on the thighs for the dOFM probe set-up (minimum length of 24 cm, 3&#xD;
             treatment sites with 4 dOFM probes).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pieber, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franz Feichtner, PhD</last_name>
    <phone>+43316876</phone>
    <phone_ext>4003</phone_ext>
    <email>franz.feichtner@joanneum.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katrin Tiffner, PhD</last_name>
    <phone>+43316876</phone>
    <phone_ext>4121</phone_ext>
    <email>katrin.tiffner@joanneum.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CTU - Clinical Trials Unit, Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Pircher</last_name>
      <phone>+43316385</phone>
      <phone_ext>72834</phone_ext>
      <email>thomas.pircher@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Eva Svehlikova, PhD</last_name>
      <phone>+43316385</phone>
      <phone_ext>72835</phone_ext>
      <email>eva.svehlikova@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Eva Svehlikova, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Pieber, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Bodenlenz M, Tiffner KI, Raml R, Augustin T, Dragatin C, Birngruber T, Schimek D, Schwagerle G, Pieber TR, Raney SG, Kanfer I, Sinner F. Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence. Clin Pharmacokinet. 2017 Jan;56(1):91-98. doi: 10.1007/s40262-016-0442-z. Erratum in: Clin Pharmacokinet. 2017 Jan;56(1):99.</citation>
    <PMID>27539717</PMID>
  </reference>
  <reference>
    <citation>Benfeldt E, Hansen SH, Vølund A, Menné T, Shah VP. Bioequivalence of topical formulations in humans: evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J Invest Dermatol. 2007 Jan;127(1):170-8. Epub 2006 Jul 27.</citation>
    <PMID>16874309</PMID>
  </reference>
  <reference>
    <citation>Bodenlenz M, Aigner B, Dragatin C, Liebenberger L, Zahiragic S, Höfferer C, Birngruber T, Priedl J, Feichtner F, Schaupp L, Korsatko S, Ratzer M, Magnes C, Pieber TR, Sinner F. Clinical applicability of dOFM devices for dermal sampling. Skin Res Technol. 2013 Nov;19(4):474-83. doi: 10.1111/srt.12071. Epub 2013 Apr 13.</citation>
    <PMID>23581539</PMID>
  </reference>
  <reference>
    <citation>Bodenlenz M, Augustin T, Birngruber T, Tiffner KI, Boulgaropoulos B, Schwingenschuh S, Raney SG, Rantou E, Sinner F. Variability of Skin Pharmacokinetic Data: Insights from a Topical Bioequivalence Study Using Dermal Open Flow Microperfusion. Pharm Res. 2020 Sep 28;37(10):204. doi: 10.1007/s11095-020-02920-x.</citation>
    <PMID>32989514</PMID>
  </reference>
  <reference>
    <citation>Dehghanyar P, Mayer BX, Namiranian K, Mascher H, Müller M, Brunner M. Topical skin penetration of diclofenac after single- and multiple-dose application. Int J Clin Pharmacol Ther. 2004 Jul;42(7):353-9.</citation>
    <PMID>15605686</PMID>
  </reference>
  <reference>
    <citation>Müller M, Mascher H, Kikuta C, Schäfer S, Brunner M, Dorner G, Eichler HG. Diclofenac concentrations in defined tissue layers after topical administration. Clin Pharmacol Ther. 1997 Sep;62(3):293-9.</citation>
    <PMID>9333105</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Dermal open flow microperfusion</keyword>
  <keyword>Dermal Pharmacokinetics Measurement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Coal Tar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

